UCB today announced new findings for Vimpat® (lacosamide) that offer additional support regarding the long-term benefits of the anti-epileptic drug (AED) as an adjunctive therapy for adults with uncontrolled partial-onset seizures.
“These data add to the growing body of support showing that Vimpat® reduces seizure frequency and improves patient-reported quality of life measures on a long-term basis,” said Aatif Husain, MD, lead author of one of the studies and Director, Clinical Neurophysiology Training Program, Duke University Medical Center.
“These results, combined with the consistent long-term tolerability profile, are important milestones for this AED.”
An open-label extension study analysed patient-reported outcomes and found that, after a year of treatment with Vimpat®, patients reported significant improvements in all aspects of seizure severity and across almost all health-related quality of life (HRQoL) assessments, including social functioning and emotional well-being.
Results of this open-label extension study demonstrated sustained efficacy in adults taking Vimpat® as adjunctive therapy up to five years, and a long-term tolerability profile consistent with that of previous Vimpat® trials.
These and other Vimpat® data were presented at the 64th annual meeting of the American Epilepsy Society (AES) in San Antonio, Texas.